Benefit-risk evaluation of Fuzheng Yiliu Decoction combined with chemotherapy for treating non-small cell lung cancer using multicriteria decision analysis.

ABSTRACT:

Introduction

This study uses multi-criteria decision analysis (MCDA) to evaluate the benefits and risks of combining Fuzheng Yiliu Decoction with chemotherapy in treating non-small cell lung cancer (NSCLC). The aim is to improve clinical outcomes for NSCLC patients by integrating traditional Chinese medicine with conventional chemotherapy.

Methods

A comprehensive literature search was conducted in PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), China Biology Medicine Disc (CBM), Wanfang Databases, and China Science and Technology Journal Database (VIP Databases) to identify relevant studies on Fuzheng Yiliu Decoction combined with chemotherapy for NSCLC. Meta-analysis using RevMan 5.3 was performed to compare the effect sizes of the two treatment regi

SUBMITTER: Ma D 

PROVIDER: S-EPMC12500661 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature